Author: Purespring Therapeutics

Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome, with new preclinical and epidemiological data presented at ASN Kidney Week 2026

October 27, 2026
Purespring Therapeutics to present new data on pipeline progress in Alport Syndrome at the American Society of Nephrology (ASN) Kidney Week 2026

October 14, 2026

Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome, with new preclinical and epidemiological data presented at ASN Kidney Week 2026